Article

May 12, 2004

Polypropylene mesh offers strength and durability

The Pelvitex polypropylene mesh from Bard Urological is comprised ofa monofilament polypropylene mesh coated with a hydrophilic porcine collagen.

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Related Content

August 4th 2025

Biopsy grade alone may underestimate risk in GG1 prostate cancer

Hannah Clarke

Data showed that 1 in 6 men with GG1 prostate cancer ultimately had higher-risk disease when other clinical features were taken into account.

August 4th 2025

Pearls & Perspectives: Tailoring BPH Therapies to the Patient, with Utsav Bansal, MD

Amy M. Pearlman, MD

Bansal unpacks how to personalize treatment plans in a therapeutic landscape now filled with minimally invasive and surgical options.

August 4th 2025

SunRISe-1 data of TAR-200 in NMIBC published in Journal of Clinical Oncology

Hannah Clarke

Data show that TAR-200 monotherapy led to high complete response rates and encouraging DFS in patients with BCG-unresponsive high-risk NMIBC.

August 4th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

August 4th 2025

Trial launches of ABO-101 for primary hyperoxaluria type 1

Hannah Clarke

The first patient has been dosed in the phase 1/2 redePHine trial, evaluating the safety and preliminary efficacy of ABO-101 for PH1.

August 4th 2025

Enzalutamide shows improved relative efficacy over darolutamide in mHSPC

Hannah Clarke

Enzalutamide plus ADT was associated with significant improvements in rPFS and time to castration resistance compared with darolutamide plus ADT.

Related Content

August 4th 2025

Biopsy grade alone may underestimate risk in GG1 prostate cancer

Hannah Clarke

Data showed that 1 in 6 men with GG1 prostate cancer ultimately had higher-risk disease when other clinical features were taken into account.

August 4th 2025

Pearls & Perspectives: Tailoring BPH Therapies to the Patient, with Utsav Bansal, MD

Amy M. Pearlman, MD

Bansal unpacks how to personalize treatment plans in a therapeutic landscape now filled with minimally invasive and surgical options.

August 4th 2025

SunRISe-1 data of TAR-200 in NMIBC published in Journal of Clinical Oncology

Hannah Clarke

Data show that TAR-200 monotherapy led to high complete response rates and encouraging DFS in patients with BCG-unresponsive high-risk NMIBC.

August 4th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

August 4th 2025

Trial launches of ABO-101 for primary hyperoxaluria type 1

Hannah Clarke

The first patient has been dosed in the phase 1/2 redePHine trial, evaluating the safety and preliminary efficacy of ABO-101 for PH1.

August 4th 2025

Enzalutamide shows improved relative efficacy over darolutamide in mHSPC

Hannah Clarke

Enzalutamide plus ADT was associated with significant improvements in rPFS and time to castration resistance compared with darolutamide plus ADT.

Polypropylene mesh offers strength and durability

Newsletter